HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

quelamycin

Also Known As:

NSC-267703; triferric doxorubicin

Networked: 5 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Gosálvez Gosálvez, M: 1 article (01/2000)

Related Diseases

1.	Cardiotoxicity 05/01/1979 - "A previous phase I study demonstrated excessive generalized toxicity (20 of 21 patients) and cardiotoxicity (eight of 21 patients) of single-day intermittent quelamycin (NSC-267703) treatment, and a modified schedule was recommended to overcome this acute toxicity. " 01/01/1980 - "Quelamycin is triferric doxorubicin, a metallic derivative of adriamycin which, in experimental studies, has been found to have a better therapeutic index than adriamycin and no cardiotoxicity. "
2.	Neoplasms (Cancer) 05/01/1979 - "Our phase I clinical study of quelamycin includes 37 patients with a wide spectrum of solid tumors. " 01/01/2000 - "It is defined the precise responsibility of the author in the discoveries of the second site of control of glycolysis, rotenone tumors, quelamycin and thioproline, filamentous mitochondria, and the technique of cancer reversal by dual strategy."
3.	Hyperthermia 02/01/1985 - "With the MM cells, hyperthermia potentiated the cytotoxic effects of doxorubicin (ADM), daunorubicin, mitoxantrone (DHAD), and quelamycin but did not enhance that of aclacinomycin (ACM). "

Related Drugs and Biologics

1.	quelamycin
2.	Doxorubicin (Adriamycin)
3.	Rotenone
4.	Mitoxantrone (Novantrone)
5.	Daunorubicin (Cerubidine)
6.	aclacinomycins
7.	thiazolidine-4-carboxylic acid